Search papers, labs, and topics across Lattice.
This study introduces a structural variant of the Factorial Hidden Markov Model (FHMM) to analyze disease trajectories in Type 2 diabetes mellitus (T2DM) patients, leveraging a combination of independent latent components linked to comorbidities and lab results. By applying this model to a comprehensive dataset from The IQVIA Medical Research Data, the authors identify distinct patient states and clustering patterns that reflect clinically relevant progression pathways of diabetes-related complications. The findings highlight the model's ability to reveal heterogeneous trajectories, including microvascular-dominant and multi-organ pathways, which are associated with varying levels of comorbidity and mortality risk.
Identifying distinct disease trajectories in T2DM reveals critical insights into patient progression and comorbidity risk that could transform clinical management.
In this work, we propose a structural variant of the Factorial Hidden Markov Model (FHMM) for the analysis of disease trajectories in patients with Type 2 diabetes mellitus (T2DM). The model represents a patient's latent health state as a combination of multiple independent, simultaneously evolving components, associated with comorbidities and lab results. This structured latent representation facilitates the identification of clinically meaningful patient states and clustering of common disease trajectories. We evaluate the proposed approach using The IQVIA Medical Research Data incorporating data from THIN, a Cegedim database of anonymized electronic health records (EHR), identifying patients with a first-ever prescription for a non-insulin antidiabetic drug (NIAD) between January 2006 and December 2019. The model identifies multiple clinically coherent latent components corresponding to known patterns of diabetes-related complications and reveals heterogeneous progression pathways, including distinct microvascular-dominant and multi-organ trajectories associated with elevated comorbidity burden and mortality. These results demonstrate that the proposed framework captures meaningful longitudinal structure in EHR data and provides interpretable insights into the evolution of T2DM and its comorbidities.
